ATAI
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase phase data dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action | ATAI
Company
Deck Type
Sector
Industry
Deck date
April 2023
Slide
18 of 30
Similar slides by ATAI
See diffirences between slides (animation)
Investor Conference
May 2023
phase data dose dependent increase in frontal beta power was demonstrated providing evidence of target engagement and mechanism of action | ATAI
Investor Presentation
March 2023
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
Investor Presentation
February 2023
changes in beta power from dose to hour post dose placebo low dose high dose no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
Investor Presentation
January 2023
changes in beta power from dose to hour post dose placebo low dose high dose no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
Related slides by other companies
Absci
Investor Presentation
October 2023
recent data illustrate increase in deal economics associated with additional internal development | Absci
Dare Bioscience
Investor Presentation
February 2023
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
Oculis
Investor Presentation
April 2023
phase a positive results in | Oculis
AvidXchange
Investor Presentation
May 2024
full year financial outlook mal | AvidXchange
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io